← Back to Screener
Cocrystal Pharma, Inc. Common Stock (COCP)
Price$1.51
Favorite Metrics
Price vs S&P 500 (26W)35.56%
Price vs S&P 500 (4W)31.68%
Market Capitalization$20.82M
All Metrics
Book Value / Share (Quarterly)$0.59
P/TBV (Annual)1.61x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.76
Price vs S&P 500 (YTD)50.31%
Gross Margin (TTM)41.18%
Net Profit Margin (TTM)-480.10%
EPS (TTM)$-0.94
10-Day Avg Trading Volume0.55M
EPS Excl Extra (TTM)$-0.94
EPS (Annual)$-1.80
ROI (Annual)-189.02%
Gross Margin (Annual)21.33%
Net Profit Margin (5Y Avg)-12981.54%
Cash / Share (Quarterly)$0.59
ROA (Last FY)-133.77%
EBITD / Share (TTM)$-0.93
ROE (5Y Avg)-78.40%
Operating Margin (TTM)-477.11%
Cash Flow / Share (Annual)$-1.62
P/B Ratio2.71x
P/B Ratio (Quarterly)2.13x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)6.51x
Net Interest Coverage (TTM)-3883.00x
ROA (TTM)-89.82%
EV / EBITDA (TTM)235763440492845472.00x
EPS Incl Extra (Annual)$-1.80
Current Ratio (Annual)4.77x
Quick Ratio (Quarterly)5.47x
3-Month Avg Trading Volume1.69M
52-Week Price Return15.27%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$26.76
P/S Ratio (Annual)10.36x
Asset Turnover (Annual)0.04x
52-Week High$2.67
Operating Margin (5Y Avg)-26916.68%
EPS Excl Extra (Annual)$-1.80
CapEx CAGR (5Y)-44.36%
26-Week Price Return42.45%
Quick Ratio (Annual)4.59x
13-Week Price Return36.04%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.78x
Enterprise Value$13.088
Asset Turnover (TTM)0.04x
Book Value / Share Growth (5Y)-36.21%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-480.10%
Cash / Share (Annual)$0.97
3-Month Return Std Dev115.35%
Net Income / Employee (TTM)$-1
ROE (Last FY)-189.02%
Net Interest Coverage (Annual)-89.72x
EPS Basic Excl Extra (Annual)$-1.80
P/FCF (TTM)10.46x
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.94
Receivables Turnover (Annual)0.00x
ROI (TTM)-129.69%
P/S Ratio (TTM)10.36x
Pretax Margin (5Y Avg)-16894.02%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$26.76
Price vs S&P 500 (52W)-19.37%
Year-to-Date Return54.24%
5-Day Price Return-1.31%
EPS Normalized (Annual)$-1.80
ROA (5Y Avg)-64.44%
Net Profit Margin (Annual)-480.10%
Month-to-Date Return49.51%
Cash Flow / Share (TTM)$-1.95
EBITD / Share (Annual)$-1.79
Operating Margin (Annual)-477.11%
LT Debt / Equity (Annual)0.01x
ROI (5Y Avg)-78.40%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.94
P/TBV (Quarterly)1.61x
P/B Ratio (Annual)2.16x
Inventory Turnover (TTM)4.43x
Pretax Margin (TTM)-480.10%
Book Value / Share (Annual)$0.94
Price vs S&P 500 (13W)33.66%
Beta1.57x
Revenue / Share (TTM)$0.00
ROE (TTM)-129.69%
52-Week Low$0.86
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
COCPCocrystal Pharma, Inc. Common Stock | 10.36x | — | 41.18% | — | $1.51 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.71 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.93x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Cocrystal Pharma develops novel antiviral therapeutics targeting influenza, hepatitis C, and norovirus using structure-based drug design and proprietary technology platforms. The company leverages Nobel Prize-winning expertise to create first-in-class and best-in-class antiviral drugs. Its lead program, CC-31244, is an oral broad-spectrum replication inhibitor in clinical development.